BATF2 CRISPR/Cas9 KO Plasmid (h): sc-403270
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- BATF2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the BATF2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: BATF2 Antibody (1B11): sc-293274
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BATF2 CRISPR/Cas9 KO Plasmid (h) | sc-403270 | 20 µg | $397.00 |
Overview
BATF2 (basic leucine zipper ATF-like transcription factor 2) is an interferon-inducible transcription factor that modulates gene expression programs downstream of cytokine and innate immune signaling. In human cells, BATF2 participates in regulating inflammatory responses and antigen presentation, with functional links to JAK/STAT and IRF-driven transcriptional networks that shape macrophage and dendritic cell activation states. It has been studied as a context-dependent regulator of cell growth, differentiation, and apoptosis, reflecting its ability to rewire transcriptional outputs during cellular stress. Altered BATF2 expression or activity has been associated with immune dysregulation and oncogenic processes, supporting its utility as a molecular node for dissecting inflammation–tumor crosstalk.
BATF2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the BATF2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the BATF2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the BATF2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish BATF2 protein expression.
This CRISPR knockout system enables efficient generation of BATF2-deficient cell models for investigation of BATF2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting BATF2 exon(s) critical for BATF2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple BATF2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by BATF2 CRISPR/Cas9 KO Plasmid (h) and BATF2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the BATF2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by BATF2 HDR Plasmid (h) and BATF2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by BATF2 homology arms to support homology-directed repair at defined BATF2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.